[Changes in and modulation of receptor activity in hepatic encephalopathy].
In hepatic encephalopathy (HE) brain uptake of large neutral amino acids is impaired with tryptophan crossing the blood brain barrier (BBB) to a much larger extent than all other competing amino acids (AA). The disturbance in the steady-state of transmitter is paralleled to the change of their kinetic data. This is reflected by an increase in serotonin (5-HT) synthesis and turnover, while the number of post-synaptic 5-HT1-binding sites is decreased, 5-HT2-receptor activity is dropping to a much smaller extent. On the other hand, presynaptic dopaminergic activity remains unchanged with no change in D2-receptor activity. Valine (VAL) improves the postsynaptic 5-HT function via modulating activity due to a regulatory mechanism at the membranal level in vitro and ex vivo. Furthermore, VAL leads to a significant reduction of serum ammonia (NH4+) and brain NH4+ concentration. VAL is able to antagonize the binding density diminishing effects of NH4+ on 5-HT binding sites. This effect could be characterized by the measurement of VAL binding sites being 5 to 10 fold higher than the number of leucin (LEU)-sites. Considering the chemical bonds involved in the attachment of biogenic amines and aminoacids (Schiff-bases equilibria) the modulating action of NH4+ on neural transmission may be clarified. Tryptamine can displace the postsynaptic binding of 5-HT in brain tissue and is a possible antagonist to physiological and pharmacological effects of 5-HT. The dynamic changes of the kinetic behaviour of tryptamine-binding might demonstrate a compensating effect as shown in an increase of tryptaminergic receptor activity. As a working hypothesis, the different relative strengths of electron-pair donor and -acceptor sites of both compounds are suggested to their complementary physiological interaction. GABA, an inhibitory transmitter of the CNS is diminished in its maximal binding capacity in severe HE and is independent of NH4+ influence. Furthermore, glutamate and aspartate-receptors decrease in experimentally induced hepatic coma. L-LEU shows modulating effects of glutamine binding. Glycin-activity is increased, while naloxone- and D-ala2-methionine-encephalinamid binding are not different from controls. These data demonstrate a different influence of various brain receptors and binding sites by HE and indicate a differentiated disturbance of (neuronal) membrane activity. Therefore disturbed interneuronal dynamics might be important pathophysiological mechanisms underlying hepatic coma.
Kienzl
E
E
Riederer
P
P
Brücke
T
T
Kleinberger
G
G
Jellinger
K
K
D000641:Ammonia / Q000378:metabolism; D000818:Animals; D001224:Aspartic Acid / Q000378:metabolism; D001667:Binding, Competitive; D001679:Biogenic Amines / Q000378:metabolism; D001812:Blood-Brain Barrier; D001921:Brain / Q000378:metabolism*; D005971:Glutamates / Q000378:metabolism; D005998:Glycine / Q000378:metabolism; D006501:Hepatic Encephalopathy / Q000378:metabolism*; D006801:Humans; D007930:Leucine / Q000378:metabolism; D008560:Membrane Fluidity; D018377:Neurotransmitter Agents / Q000378:metabolism; D011956:Receptors, Cell Surface / Q000378:metabolism*; D011954:Receptors, Dopamine / Q000378:metabolism; D011985:Receptors, Serotonin / Q000378:metabolism; D012702:Serotonin Antagonists / Q000378:metabolism; D009435:Synaptic Transmission; D014363:Tryptamines / Q000378:metabolism; D014633:Valine / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D001679:Biogenic Amines; D005971:Glutamates; D018377:Neurotransmitter Agents; D011956:Receptors, Cell Surface; D011954:Receptors, Dopamine; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D014363:Tryptamines; D001224:Aspartic Acid; C030820:tryptamine; D005680:gamma-Aminobutyric Acid; D000641:Ammonia; D007930:Leucine; D014633:Valine; D005998:Glycine
Veränderungen und Modulation der Rezeptoraktivität bei hepatischer Enzephalopathie.